Profile

Glenn J. Lesser, M.D.Wake Forest Baptist Health

Doctor Rating

4.7 out of 5

113 Ratings
10 Comments
 

Glenn J. Lesser, M.D.

Professor,


Clinical Interests

Neuro-oncology, Cancer Pain Control, Cancer Symptom Management, Brain Tumors

Contact Information

Returning Patient Appointments: 336-713-5440
Department: 336-713-5440

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.A., Duke University, 1983
  • M.D., Penn State University College of Medicine, 1987
  • Residency, Internal Medicine, NC Baptist Hospital, 1991
  • Fellowship, Johns Hopkins University Schoo, 1994
  • Internship, Internal Medicine, NC Baptist Hospital, 1998

Board Certifications

  • American Board of Internal Medicine, Medical Oncology

Memberships

  • North Carolina Medical Assn
  • Society of Neuro-Oncology
  • Southern Assn For Oncology
  • Southern Medical Association
  • Am Coll of Physicians Fellow
  • Am Medical Assn
  • Am Soc of Clinical Oncology

NPI Number

  • 1205810660
Glenn J. Lesser, M.D.

Doctor Rating

4.7 out of 5

113 Ratings
10 Comments
 

Glenn J. Lesser, M.D.

Professor, Hematology & Oncology
Neurosurgery
Anesthesiology

Research Interests

Brain Neoplasms; Glioma; Antineoplastic Agents; Central Nervous System Neoplasms; Glioblastoma
More »

Contact Information

Academic: 336-716-9527 | Department: 336-713-5440

Media Medical Expert »

Recent Publications

A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. Lawrence JA, Griffin L, Balcueva EP, Groteluschen DL, Samuel TA, Lesser GJ, Naughton MJ, Case LD, Shaw EG, Rapp SR.. J Cancer Surviv. 2016;10(1):176-184.

Treatment of brain metastases of lung cancer in the era of precision medicine. Haughton ME, Chan MD, Watabe K, Bonomi M, Debinski W, Lesser GJ, Ruiz J.. Front Biosci (Elite Ed). 2016;8():219-232.

Making the most of the imaging we have: using head MRI to estimate body composition. Lack CM, Lesser GJ, Umesi UN, Bowns J, Chen MY, Case D, Hightower RC, Johnson AJ.. Clin Radiol. 2016;71(4):402.e1-7.

Creating clinical trial designs that incorporate clinical outcome assessments. Gilbert MR, Rubinstein L, Lesser G.. Neuro Oncol. 2016;18(Suppl 2):ii21-ii25.

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-beta tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG.. Neuro Oncol. 2016;():.

Repeatability of 18F-FLT PET in a multi-center study of patients with high grade glioma. Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Mountz JM, Lieberman FS, Fisher JD, Desideri S, Ye X, Grossman SA, Schiff D, Wahl RL.. J Nucl Med. 2016;():.

Genomic predictors of imaging response and survival in glioblastoma [abstract]. Soike M, McTyre E, Holmes JA, Paulsson AK, Miller L, Lesser GJ, Strowd RE, Johnson A, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD.. Int J Radiat Oncol Biol Phys. 2016;96(2 Suppl):E121-E122.

Hemolytic anemia in two patients with glioblastoma multiforme: a possible interaction between vorinostat and dapsone. Lewis JA, Petty WJ, Harmon M, Peacock JE, Valente K, Owen J, Pirmohamed M, Lesser GJ.. J Oncol Pharm Pract. 2015;21(3):220-223.

Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of radiation therapy oncology group 0424. Fisher BJ, Hu C, Macdonald DR, Lesser GJ, Coons SW, Brachman DG, Ryu S, Werner-Wasik M, Bahary JP, Liu J, Chakravarti A, Mehta M.. Int J Radiat Oncol Biol Phys. 2015;91(3):497-504.

Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors. Mirlohi S, Duncan SE, Harmon M, Case D, Lesser G, Dietrich AM.. Clin Oral Investig. 2015;19(1):127-137.

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY.. J Neurooncol. 2015;121(2):297-302.

Anaplastic ganglioglioma: a report of three cases and review of the literature. Lucas JT Jr, Huang AJ, Mott RT, Lesser GJ, Tatter SB, Chan MD.. J Neurooncol. 2015;123(1):171-177.

Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Page BR, Shaw EG, Lu L, Bryant D, Grisell D, Lesser GJ, Monitto DC, Naughton MJ, Rapp SR, Savona SR, Shah S, Case D, Chan MD.. Neuro Oncol. 2015;17(10):1393-1401.

Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107 [abstract]. Armstrong TS, Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu JJ, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, Gruber ML, Lesser GJ, Pan E, Kesari S, Yu J.. J Clin Oncol. 2015;33(15 Suppl):2036.

Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106. Greven KM, Case LD, Nycum LR, Zekan PJ, Hurd DD, Balcueva EP, Mills GM, Zon R, Flynn PJ, Biggs D, Shaw EG, Lesser G, Naughton MJ.. J Community Support Oncol. 2015;13(3):87-94.

Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: a phase I Adult Brain Tumor Consortium study [abstract]. Holdhoff M, Ye XB, Nabors LB, Desai AS, Mikkelsen T, Lesser G, Read WL, Lieberman FS, Supko J, Fisher JD, Desideri S, Grossman SA, Schiff D.. J Clin Oncol. 2015;33(15 Suppl):2033.

Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance) [abstract]. Laack NN, Galanis E, Anderson SK, Leinweber C, Buckner JC, Giannini C, Geoffroy FJ, Johnson DR, Lesser GJ, Jaeckle KA, Sarkaria JN.. J Clin Oncol. 2015;33(15 Suppl):2013.

Quality of life analysis of NCCTG N0877 (Alliance): phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM)[abstract]. Qin R, Tan AD, Sloan JA, Johnson DR, Lesser GJ, Anderson SK, Laack NN.. J Clin Oncol. 2015;33(15 Suppl):e17715.

Mild cognitive impairment (MCI) in chemotherapy-treated breast cancer survivors [abstract]. Gifford A, Lawrence J, Case D, Rapp S, Baker L, Craft S, Groteluschen DL, Klepin H, Lesser G, Naughton MJ, Sachs B, Samuel TA, Sink K, Williamson, J, Shaw EG.. J Clin Oncol. 2015;33(15 Suppl):9560.

Immunologic response to high-dose influenza vaccination in patients with primary central nervous system malignancy (PCNSM) [abstract]. Strowd RE, Russell G, Harmon M, Carter AF, Chan MD, Tatter SB, Laxton AW, High K, Lesser G.. J Clin Oncol. 2015;33(15 Suppl):e20669.

Preliminary efficacy of an enhanced quitline smoking cessation intervention for cancer patients [abstract]. Weaver KE, Urbanic JJ, Case D, Kaplan SG, Lesser GJ, Zbikowski S, Bryant D, Dakhil SR, Wilson C, Shaw EG, Danhauer S.. J Clin Oncol. 2015;33(15 Suppl):e20671.

A prospective evaluation of radiotherapy (RT) related skin reactions in a multi-racial/ethnic population of women with newly diagnosed breast cancer (BC) [abstract]. Urbanic JJ, Case D, Baez-Diaz L, Brown DR, Strasser J, Enevold G, Naughton M, Weaver KE, Baglan K, Bryant D, Langefeld C, Lad TE, Lee L, Rine G, Curtis AE, Koprowski CD, Tomlinson WV, Lesser GJ, Shaw EG, Hu JJ,.. J Clin Oncol. 2015;33(15 Suppl):6593.

Bevacizumab and glioblastoma: the ecstasy and the agony [editorial]. Lesser GJ.. Oncology (Williston Park). 2015;29(10):728-729.

Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Neurooncol. 2015;124(3):447-453.

Late breast toxicity rates in a prospective evaluation of radiation therapy (RT) in a multiracial/ethnic population of breast cancer (BC) patient [abstract]. Urbanic JJ, Case D, Baez-Diaz L, Brown DR, Strasser J, Enevold G, Naughton M, Weaver KE, Baglan K, Bryant D, Langefeld C, Lad T, Lee L, Rine GP, Curtis AE, Koprowski CD, Tomlinson WV, Lesser GJ, Shaw EG, Hu J.. Int J Radiat Oncol Biol Phys. 2015;93(3 Suppl):E50-E51.

Outcomes for anaplastic glioma treated with radiation therapy with or without concurrent temozolomide [abstract]. McTyre E, Lucas JT Jr, Helis C, Farris M, Houseknecht K, Mott R, Laxton AW, Tatter SB, Lesser GJ, Chan MD.. Int J Radiat Oncol Biol Phys. 2015;93(3 Suppl):E108.

Oxidative DNA damage in radiation therapy related early adverse skin reactions in breast cancer [abstract]. Hu J, Nelson O, Takita C, Case D, Wright JL, Lee E, Baez-Diaz L, Brown DR, Strasser J, Enevold G, Baglan K, Bryant D, Lad T, Lee L, Rine GP, Curtis AE, Koprowski CD, Tomlinson WV, Lesser GJ, Shaw EG, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2015;93(3 Suppl):S108.

Relapsing intracranial plasma cell granuloma: a case report. Renfrow JJ, Mitchell JW, Goodman M, Mellen LA, Wilson JA, Mott RT, Lesser GJ.. Oncol Lett. 2014;7(2):531-533.

Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD.. Am J Clin Oncol. 2014;37(2):177-181.

Influenza vaccine immunogenicity in patients with primary central nervous system malignancy. Strowd RE, Swett K, Harmon M, Carter AF, Pop-Vicas A, Chan M, Tatter SB, Ellis T [deceased], Blevins M, High K, Lesser GJ.. Neuro Oncol. 2014;16(12):1639-1644.

Taste and smell disturbances after brain irradiation: a dose-volume histogram analysis of a prospective observational study. Leyrer CM, Chan MD, Peiffer AM, Horne E, Harmon M, Carter AF, Hinson WH, Mirlohi S, Duncan SE, Dietrich AM, Lesser GJ.. Pract Radiat Oncol. 2014;4(2):130-135.

Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Neurooncol. 2014;119(2):429-435.

Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery. Huang AJ, Huang KE, Page BR, Ayala-Peacock DN, Lucas JT Jr, Lesser GJ, Laxton AW, Tatter SB, Chan MD.. J Neurooncol. 2014;120(1):163-169.

Incidence of mild cognitive impairment in irradiated brain tumor survivors [abstract]. Shaw E, McKee N, Case D, Lawrence J, Lesser G, Naughton M, Peiffer A, Loghin M, Giguere J, Stieber V, Rapp S.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S162-S163.

L-arginine - based nutritional supplement did not improve erectile function or quality of life in prostate cancer survivors previously treated with radiation therapy: results of CCOP research base protocol 98110-A randomized phase 2 dose. Urbanic JJ, Case D, Lesser G, Enevold G, Naughton M, Danhauer S, Rapp S, Vitolins M, Johnson S, McCollough M, Duncan D, Papagikos M, Shaw EG.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S86-S87.

Genomic predictors of infield and marginal failure for glioblastoma treated with concurrent radiation therapy and temozolomide: a step towards personalized radiation fields? [abstract]. Holmes JA, Paulsson A, Peiffer AM, Miller LD, Xu J, Hinson WH, Lesser GJ, Tatter SB, Debinski W, Chan MD.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S291-S292.

Cellular microparticles as blood-borne endothelial biomarkers in patients with malignant gliomas [abstract]. Lesser G, Harmon M, Khan I, Whitlow C, Brown W.. Neuro Oncol. 2014;16(Suppl 5):v27.

A pilot study of high-dose influenza vaccine immunogenicity in patients with primary central nervous system malignancy [abstract]. Strowd R, Russell G, Harmon M, Carter A, Chan M, Tatter S, Laxton A, High K, Lesser G.. Neuro Oncol. 2014;16(Suppl 5):v207.

A randomized double blind placebo-controlled phase 2 trial of dendritic cell (DC) vaccine ICT-107 following standard treatment in newly diagnosed patients with GBM [abstract]. Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W, Zhu JJ, Glantz M, Peereboom D, Markert J, Larocca R, O'Rourke D, Fink K, Kim L, Gruber M, Lesser G, Pan E, Kesari S, Yu J.. Neuro Oncol. 2014;16(Suppl 5):v22.

Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature. Vincent A, Lesser G, Brown D, Vern-Gross T, Metheny-Barlow L, Lawrence J, Chan M.. J Breast Cancer. 2013;16(1):122-126.

A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, Naughton MJ, Vitolins MZ, Lively MO, Shaw EG.. J Support Oncol. 2013;11(1):31-42.

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY.. Neuro Oncol. 2013;15(7):930-935.

Somatostatin receptor molecular imaging for metastatic intracranial hemangiopericytoma. Kota G, Gupta P, Lesser GJ, Wilson JA, Mintz A.. Clin Nucl Med. 2013;38(12):984-987.

Malignant transformation of an intramedullary epidermoid cyst in the thoracic region of the spinal cord: case report. Somasundaram A, Lesser GJ, Mott RT, Hsu W.. J Neurosurg Spine. 2013;19(5):591-594.

Impact of temozolomide on gonadal function in patients with primary malignant brain tumors. Strowd RE, Blackwood R, Brown M, Harmon M, Lovato J, Yalcinkaya T, Lesser G.. J Oncol Pharm Pract. 2013;19(4):321-327.

Molecular subtyping of brain metastases and implications for therapy. Renfrow JJ, Lesser GJ.. Curr Treat Options Oncol. 2013;14(4):514-527.

An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy. Morrell RM, Tooze JA, Harmon MS, Carter AF, DeTroye AT, Lesser GJ.. J Oncol Pract. 2013;9(5):E268-E271.

Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. Vitolins MZ, Griffin L, Tomlinson WV, Vuky J, Adams PT, Moose D, Frizzell B, Lesser GJ, Naughton M, Radford JE Jr, Shaw EG.. J Clin Oncol. 2013;31(32):4092-4098.

Phase II trial of triple receptor tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas [abstract]. Norden A, Schiff D, Ahluwalia M, Lesser G, Nayak L, Lee E, Muzikansky A, Dietrich J, Smith K, Gaffey S, McCluskey C, Ligon K, Reardon D, Wen P.. Neuro Oncol. 2013;15(Suppl 3):123-124.

Phase II study of monthly pasireotide lar (Som230C) for recurrent or progressive meningioma: final results [abstract]. Norden A, Hammond S, Drappatz J, Phuphanich S, Reardon D, Wong E, Plotkin S, Lesser G, Raizer J, Batchelor T, Lee E, Kaley T, Muzikansky A, Doherty L, LaFrankie D, Ruland S, Smith K, Gerard M, McCluskey C, Wen P.. Neuro Oncol. 2013;15(Suppl 3):123.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Interests

Neuro-oncology, Cancer Pain Control, Cancer Symptom Management, Brain Tumors
Glenn J. Lesser, M.D.

Glenn J. Lesser, M.D.

Professor, Hematology & Oncology
Neurosurgery
Anesthesiology

Doctor Rating

4.7 out of 5

Glenn J. Lesser, M.D.113 Ratings
10 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.8
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.8
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.8
Time CP spent with patient
4.8
Wait time at clinic
3.9



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

9/29/2016

Always a positive, good experience.

8/31/2016

the doctor is very kind very courtious.

7/23/2016

*Dr. Lesser is a very good Dr. Very pleased with all his time & effort to treat husbands cancer.

7/18/2016

Good experience.

6/9/2016

*Dr. Lesser is caring and knowledgeable. His phone call to our home to confirm MRi findings was reassuring and appreciated.

5/26/2016

Dr Lesser wasn't my favorite at first probably because I was scared and didn't know which way to turn but now that he has been my provider all this time I would not trade him for any other provider!! He showed patience and understanding and I feel that he treated my condition very well. Dr Lesser is an amazing Doctor and if God forbid any of my friends or family would need an oncologist I would definitely recommend him!

5/22/2016

dr. Lesser is very knowledgeable and professional, but I feel that he still sees me as an individual patient with real needs.

3/18/2016

Good.

3/7/2016

I have already recommended *Dr. Lesser and Wake Forest Baptist to several people.

1/15/2016

*Dr. Lesser is just great. He's very caring and easy to talk with about your health and concerns.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.